These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25359717)

  • 1. The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.
    Edwards MA; Crombie K; Schramm C; Krenz M
    J Appl Physiol (1985); 2015 Jan; 118(1):124-31. PubMed ID: 25359717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.
    Schramm C; Fine DM; Edwards MA; Reeb AN; Krenz M
    Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H231-43. PubMed ID: 22058153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
    Krenz M; Yutzey KE; Robbins J
    Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.
    Roy R; Krenz M
    J Mol Cell Cardiol; 2017 Nov; 112():83-90. PubMed ID: 28911943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.
    Clay SA; Domeier TL; Hanft LM; McDonald KS; Krenz M
    Am J Physiol Heart Circ Physiol; 2015 May; 308(9):H1086-95. PubMed ID: 25724491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LEOPARD-type SHP2 mutant Gln510Glu attenuates cardiomyocyte differentiation and promotes cardiac hypertrophy via dysregulation of Akt/GSK-3β/β-catenin signaling.
    Ishida H; Kogaki S; Narita J; Ichimori H; Nawa N; Okada Y; Takahashi K; Ozono K
    Am J Physiol Heart Circ Physiol; 2011 Oct; 301(4):H1531-9. PubMed ID: 21803945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of ERK1/2 signaling in congenital valve malformations in Noonan syndrome.
    Krenz M; Gulick J; Osinska HE; Colbert MC; Molkentin JD; Robbins J
    Proc Natl Acad Sci U S A; 2008 Dec; 105(48):18930-5. PubMed ID: 19017799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish.
    Bonetti M; Paardekooper Overman J; Tessadori F; Noël E; Bakkers J; den Hertog J
    Development; 2014 May; 141(9):1961-70. PubMed ID: 24718990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines.
    Yi JS; Perla S; Enyenihi L; Bennett AM
    JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32584792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.
    Lauriol J; Cabrera JR; Roy A; Keith K; Hough SM; Damilano F; Wang B; Segarra GC; Flessa ME; Miller LE; Das S; Bronson R; Lee KH; Kontaridis MI
    J Clin Invest; 2016 Aug; 126(8):2989-3005. PubMed ID: 27348588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the catalytic activity of LEOPARD syndrome-associated SHP2 mutants toward parafibromin, a bona fide SHP2 substrate involved in Wnt signaling.
    Noda S; Takahashi A; Hayashi T; Tanuma S; Hatakeyama M
    Biochem Biophys Res Commun; 2016 Jan; 469(4):1133-9. PubMed ID: 26742426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy.
    Wang J; Chandrasekhar V; Abbadessa G; Yu Y; Schwartz B; Kontaridis MI
    PLoS One; 2017; 12(6):e0178905. PubMed ID: 28582432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
    Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
    Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.
    Jopling C; van Geemen D; den Hertog J
    PLoS Genet; 2007 Dec; 3(12):e225. PubMed ID: 18159945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.
    Schramm C; Edwards MA; Krenz M
    J Biol Chem; 2013 Jun; 288(25):18335-44. PubMed ID: 23673659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.
    Hartman ZR; Schaller MD; Agazie YM
    Mol Cancer Res; 2013 Jun; 11(6):651-64. PubMed ID: 23512980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2.
    Khare S; Holgren C; Samarel AM
    Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1100-12. PubMed ID: 16920701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.
    Tajan M; Batut A; Cadoudal T; Deleruyelle S; Le Gonidec S; Saint Laurent C; Vomscheid M; Wanecq E; Tréguer K; De Rocca Serra-Nédélec A; Vinel C; Marques MA; Pozzo J; Kunduzova O; Salles JP; Tauber M; Raynal P; Cavé H; Edouard T; Valet P; Yart A
    Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4494-503. PubMed ID: 25288766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.